腫瘤病理的分子檢測腫瘤病理的分子檢測1分子病理常用檢測技術(shù)Hagman-ARMS(與國際獲批的技術(shù)相當(dāng))DNA測序(基因突變檢測的金標(biāo)準(zhǔn)技術(shù))NGSFISH分子病理常用檢測技術(shù)2相關(guān)的信號通路創(chuàng)9吧PI3K-AKT(AKT)信號通路PI3KHdommTORC2er473AKTPTK=proteintyrosinemTORCVApoptosisCrno相關(guān)的信號通路創(chuàng)9吧3相關(guān)的信號通路-Ras-Raf-MEK-ERK(MAPK)信號通路RTKcellmembraneactivecytoplasm…CostelloSyndromeSosGrb2(Shp2R計CFCSyndromeNoonanSyndromeMEIERKnucleusERK相關(guān)的信號通路-Ras-Raf-MEK-ERK(MAPK)信4+1962-StanleyCohendiscoversEGFinmice+)1977-IdentificationofegFRbyCohenEGFRhistory+1980-DemanstrationthatEGFRhasintrinsickinaseactivity+)1981-JohnMendesohnconductsresearchfocusingonEGFR-proposesEGasanticancertarget+1984-HumanEGFRclonedandsequencedLate1980s-MountingevidenceforEGFRimportance+1990-FirstclinicaltrialofantF-EGFRagent(monoclonalantibody)confirmsmodeofaction+1994-NewclassofEGFR-tyrosinekinaseinhibitorsdiscovered2019-Anti-tumouractivityshowninPhasellresults+2019-Gefitinibapprovedfornon-smallcelllungcancerinJapan+2019-ErlotinibapprovedbyFDafornon-smallcelllungcancer+1962-StanleyCohendiscovers5腫瘤病理分子檢測課件6腫瘤病理分子檢測課件7腫瘤病理分子檢測課件8腫瘤病理分子檢測課件9腫瘤病理分子檢測課件10腫瘤病理分子檢測課件11腫瘤病理分子檢測課件12腫瘤病理分子檢測課件13腫瘤病理分子檢測課件14腫瘤病理分子檢測課件15腫瘤病理分子檢測課件16腫瘤病理分子檢測課件17腫瘤病理分子檢測課件18腫瘤病理分子檢測課件19腫瘤病理分子檢測課件20腫瘤病理分子檢測課件21腫瘤病理分子檢測課件22腫瘤病理分子檢測課件23腫瘤病理分子檢測課件24腫瘤病理分子檢測課件25腫瘤病理分子檢測課件26腫瘤病理分子檢測課件27腫瘤病理分子檢測課件28腫瘤病理分子檢測課件29腫瘤病理分子檢測課件30腫瘤病理分子檢測課件31腫瘤病理分子檢測課件32腫瘤病理分子檢測課件33腫瘤病理分子檢測課件34腫瘤病理分子檢測課件35腫瘤病理分子檢測課件36腫瘤病理的分子檢測腫瘤病理的分子檢測37分子病理常用檢測技術(shù)Hagman-ARMS(與國際獲批的技術(shù)相當(dāng))DNA測序(基因突變檢測的金標(biāo)準(zhǔn)技術(shù))NGSFISH分子病理常用檢測技術(shù)38相關(guān)的信號通路創(chuàng)9吧PI3K-AKT(AKT)信號通路PI3KHdommTORC2er473AKTPTK=proteintyrosinemTORCVApoptosisCrno相關(guān)的信號通路創(chuàng)9吧39相關(guān)的信號通路-Ras-Raf-MEK-ERK(MAPK)信號通路RTKcellmembraneactivecytoplasm…CostelloSyndromeSosGrb2(Shp2R計CFCSyndromeNoonanSyndromeMEIERKnucleusERK相關(guān)的信號通路-Ras-Raf-MEK-ERK(MAPK)信40+1962-StanleyCohendiscoversEGFinmice+)1977-IdentificationofegFRbyCohenEGFRhistory+1980-DemanstrationthatEGFRhasintrinsickinaseactivity+)1981-JohnMendesohnconductsresearchfocusingonEGFR-proposesEGasanticancertarget+1984-HumanEGFRclonedandsequencedLate1980s-MountingevidenceforEGFRimportance+1990-FirstclinicaltrialofantF-EGFRagent(monoclonalantibody)confirmsmodeofaction+1994-NewclassofEGFR-tyrosinekinaseinhibitorsdiscovered2019-Anti-tumouractivityshowninPhasellresults+2019-Gefitinibapprovedfornon-smallcelllungcancerinJapan+2019-ErlotinibapprovedbyFDafornon-smallcelllungcancer+1962-StanleyCohendiscovers41腫瘤病理分子檢測課件42腫瘤病理分子檢測課件43腫瘤病理分子檢測課件44腫瘤病理分子檢測課件45腫瘤病理分子檢測課件46腫瘤病理分子檢測課件47腫瘤病理分子檢測課件48腫瘤病理分子檢測課件49腫瘤病理分子檢測課件50腫瘤病理分子檢測課件51腫瘤病理分子檢測課件52腫瘤病理分子檢測課件53腫瘤病理分子檢測課件54腫瘤病理分子檢測課件55腫瘤病理分子檢測課件56腫瘤病理分子檢測課件57腫瘤病理分子檢測課件58腫瘤病理分子檢測課件59腫瘤病理分子檢測課件60腫瘤病理分子檢測課件61